What we say:
Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Deafness: A therapeutic mix encompassing 3-O-laurylglyceryl ascorbate (VC-3LG), Cholecalciferol, Ajoene and DIM (VC-3LGCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via up regulation of its target genes
[easy_payment currency=”USD”]
From Significance of the study to Public health relevance:
Given that: (1) more than one seventh of the global population suffers from hearing impairment; (2) majority of hearing impairment occurs in low and middle income countries, for instance, 3 in 1000 from developed countries, while 6 in 1000 from developing countries suffer from hearing impairment; (3) damage to the auditory hair cells (HCs) is the principal reason for hearing loss; (4) only in 50% cases hearing impairment can be cured; and (5) the global annual economic cost spent for unaddressed hearing loss is estimated to be in the range of $750–790 billions, there is an urgent need to find: (i) a way to promote regeneration, growth and proliferation of auditory hair cells in mammalian cochlea; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, hearing impairment.
From Research findings to Therapeutic opportunity:
This study provides, for the first time, mechanistic insights into how a pharmaceutical mixture encompassing 3-O-laurylglyceryl ascorbate (VC-3LG), Cholecalciferol, Ajoene and DIM (VC-3LGCAD) may aid in the treatment of hearing impairment.
VC-3LGCAD, by increasing the expression of its target genes, it may increase the expression of ATG5 (Autophagy-related protein 5). Thereby, it may: (1) prevent degeneration of adult hair cells; (2) prevent aggregation of polyubiquitinated proteins and p62/SQSTM1 in inclusion bodies; (3) promote maintenance of hair cells morphology and hearing acuity; and (4) prevent hearing loss. Thus, pharmacological mixture encompassing “3-O-laurylglyceryl ascorbate (VC-3LG), Cholecalciferol, Ajoene and DIM (VC-3LGCAD) or their analogues, either alone or in combination with other drugs, may be used to treat deafness (Fig.1).
Figure 1 Mechanistic insights into how a therapeutic mix encompassing 3-O-laurylglyceryl ascorbate (VC-3LG), Cholecalciferol, Ajoene and DIM (VC-3LGCAD) aids in improving hearing impairment. VC-3LGCAD prevents aggregation of proteins, promotes regeneration of adult hair cells and inhibits hearing impairment via up-regulation of its target gene ATG5
[easy_payment currency=”USD”]
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does a therapeutic mix encompassing 3-O-laurylglyceryl ascorbate (VC-3LG), Cholecalciferol, Ajoene and DIM (VC-3LGCAD) increase the expression of ATG5?
Amount: $500#
For payment and purchase details, you may reach us at admin@genomediscovery.org
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Natural product-based therapy for Deafness: A therapeutic mix encompassing 3-O-laurylglyceryl ascorbate (VC-3LG), Cholecalciferol, Ajoene and DIM (VC-3LGCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via up regulation of its target genes, 11/November/2017, 11.33 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at admin@genomediscovery.org